Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Derma Sciences has reported that it will start a Phase II clinical development of DSC127, a novel and rapid wound-healing and scar-reduction product that has a unique mechanism of action potentially linked to the body's own, naturally occurring stem cells.
Subscribe to our email newsletter
The Phase II study for DSC127, which will be focused on diabetic foot ulcers, is scheduled to begin enrollment in the third quarter of 2008. Derma Sciences obtained the rights to DSC127 via license with the University of Southern California, and has also signed a clinical services agreement with US Biotest. The scope of the agreement covers pre-study services, study management, clinical operations, data management and medical writing.
Ed Quilty, CEO of Derma Sciences, said: “The development of DSC127 is an important milestone for Derma Sciences because it represents an opportunity for us to enter two of the largest and fastest-growing wound care markets in the world today.”